369 related articles for article (PubMed ID: 29392371)
1. Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study.
Morrison RL; Fedgchin M; Singh J; Van Gerven J; Zuiker R; Lim KS; van der Ark P; Wajs E; Xi L; Zannikos P; Drevets WC
Psychopharmacology (Berl); 2018 Apr; 235(4):1107-1119. PubMed ID: 29392371
[TBL] [Abstract][Full Text] [Related]
2. Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program.
Doherty T; Wajs E; Melkote R; Miller J; Singh JB; Weber MA
CNS Drugs; 2020 Mar; 34(3):299-310. PubMed ID: 31994024
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
[TBL] [Abstract][Full Text] [Related]
4. The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study.
van de Loo AJAE; Bervoets AC; Mooren L; Bouwmeester NH; Garssen J; Zuiker R; van Amerongen G; van Gerven J; Singh J; der Ark PV; Fedgchin M; Morrison R; Wajs E; Verster JC
Psychopharmacology (Berl); 2017 Nov; 234(21):3175-3183. PubMed ID: 28755104
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
[TBL] [Abstract][Full Text] [Related]
6. Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
Doty RL; Popova V; Wylie C; Fedgchin M; Daly E; Janik A; Ochs-Ross R; Lane R; Lim P; Cooper K; Melkote R; Jamieson C; Singh J; Drevets WC
CNS Drugs; 2021 Jul; 35(7):781-794. PubMed ID: 34235612
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
[TBL] [Abstract][Full Text] [Related]
8. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
Wajs E; Aluisio L; Holder R; Daly EJ; Lane R; Lim P; George JE; Morrison RL; Sanacora G; Young AH; Kasper S; Sulaiman AH; Li CT; Paik JW; Manji H; Hough D; Grunfeld J; Jeon HJ; Wilkinson ST; Drevets WC; Singh JB
J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32316080
[TBL] [Abstract][Full Text] [Related]
9. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).
Fu DJ; Ionescu DF; Li X; Lane R; Lim P; Sanacora G; Hough D; Manji H; Drevets WC; Canuso CM
J Clin Psychiatry; 2020 May; 81(3):. PubMed ID: 32412700
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Canuso CM; Singh JB; Fedgchin M; Alphs L; Lane R; Lim P; Pinter C; Hough D; Sanacora G; Manji H; Drevets WC
Am J Psychiatry; 2018 Jul; 175(7):620-630. PubMed ID: 29656663
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Cognition Support Formula® on cognitive function in older adults with subjective cognitive impairment: a protocol for a 26-week, randomised, double-blind, placebo-controlled trial.
Cave AE; Chang DH; Münch GW; Steiner GZ
Trials; 2019 Jun; 20(1):345. PubMed ID: 31182153
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, placebo-controlled, crossover study of the effects of lisdexamfetamine dimesylate and mixed amphetamine salts on cognition throughout the day in adults with attention-deficit/hyperactivity disorder.
Martin PT; Corcoran M; Zhang P; Katic A
Clin Drug Investig; 2014 Feb; 34(2):147-57. PubMed ID: 24297663
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.
Takahashi N; Yamada A; Shiraishi A; Shimizu H; Goto R; Tominaga Y
BMC Psychiatry; 2021 Oct; 21(1):526. PubMed ID: 34696742
[TBL] [Abstract][Full Text] [Related]
15. Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II).
Ionescu DF; Fu DJ; Qiu X; Lane R; Lim P; Kasper S; Hough D; Drevets WC; Manji H; Canuso CM
Int J Neuropsychopharmacol; 2021 Jan; 24(1):22-31. PubMed ID: 32861217
[TBL] [Abstract][Full Text] [Related]
16. The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder.
Dijkstra FM; van de Loo AJ; Abdulahad S; Bosma ER; Hartog M; Huls H; Kuijper DC; de Vries E; Solanki B; Singh J; Aluisio L; Zannikos P; Stuurman FE; Jacobs GE; Verster JC
J Psychopharmacol; 2022 May; 36(5):614-625. PubMed ID: 35212235
[TBL] [Abstract][Full Text] [Related]
17. Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.
Singh JB; Fedgchin M; Daly E; Xi L; Melman C; De Bruecker G; Tadic A; Sienaert P; Wiegand F; Manji H; Drevets WC; Van Nueten L
Biol Psychiatry; 2016 Sep; 80(6):424-431. PubMed ID: 26707087
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study.
Carr DB; Goudas LC; Denman WT; Brookoff D; Staats PS; Brennen L; Green G; Albin R; Hamilton D; Rogers MC; Firestone L; Lavin PT; Mermelstein F
Pain; 2004 Mar; 108(1-2):17-27. PubMed ID: 15109503
[TBL] [Abstract][Full Text] [Related]
19. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Dean RL; Hurducas C; Hawton K; Spyridi S; Cowen PJ; Hollingsworth S; Marquardt T; Barnes A; Smith R; McShane R; Turner EH; Cipriani A
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD011612. PubMed ID: 34510411
[TBL] [Abstract][Full Text] [Related]
20. Effects of esketamine on postoperative negative emotions and early cognitive disorders in patients undergoing non-cardiac thoracic surgery: A randomized controlled trial.
Luo T; Deng Z; Ren Q; Mu F; Zhang Y; Wang H
J Clin Anesth; 2024 Aug; 95():111447. PubMed ID: 38522144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]